The Journal of Immunology · 2001 · 41 citations · 34 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-based ImmunotherapyImmunotherapy For Solid TumorsT Cell Responses To TumorsTumor-associated AntigensLocal AdministrationManagement Of Large TumorsT Cell-based ImmunotherapyT Cell-mediated Tumor KillingTransgenic MiceTumor Antigen-based ImmunotherapyTumor ImmunogenicityTumor-specific T Cell Activation
Cytotoxic T cells recognize tumor Ags and destroy cancer cells in vitro. Adoptive transfer studies with transgenic T cells specific for tumor Ags have demonstrated that CTL are effective only in mice with small tumor burdens and thus appear to have limited potential in cancer immunotherapy. Here we used transgenic mice that express the TCR specific for an unmutated tumor Ag P1A and multiple lineages of P1A-expressing tumors to address this critical issue. We found that local costimulation, either by expression of B7-1 on the tumor cells or by local administration of anti-CD28 mAb 37N, reinvigorated the function of CTL specific for the tumor Ag, as it substantially increased the efficacy of CTL therapy for mice with large tumor burdens. Our study suggests that CTL-based immunotherapy can be manipulated to deal with large tumors.
34
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison · Science · 1996 · 3.9K citations
Life Sciences, Immunology, Oncology +17
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · Immunity · 1994 · 2.2K citations
CTLA-4 is a second receptor for the B cell activation antigen B7.
Peter S. Linsley, William Brady, M Urnes et al. · The Journal of Experimental Medicine · 1991 · 1.7K citations · Full text
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Alex Y. Huang, Paul T. Golumbek, Mojgan Ahmadzadeh et al. · Science · 1994 · 1.2K citations
Life Sciences, Immunology, Oncology +17